Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of RM-493 in healthy, overweight/obese, non-diabetic volunteers has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• RM-493 (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Overweight, Obese | Phase 1 | Status: COMPLETED